Company news

Veru Inc. news in 2026

Veru Inc.'s news releases, calls and decks from 2026, newest first.

View company

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

September 8, 2026

Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference

September 2, 2026

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

August 10, 2026

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

August 4, 2026

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

August 3, 2026

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

July 30, 2026

Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

July 27, 2026

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

July 7, 2026

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

May 13, 2026

Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th

May 6, 2026

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

March 8, 2026

Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 19, 2026

Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

February 11, 2026

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

February 4, 2026

Calls in 2026

Decks in 2026